4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $19,947.00 in Stock

by · The Markets Daily

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT – Get Free Report) insider Scott Bizily sold 1,635 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $12.20, for a total value of $19,947.00. Following the completion of the transaction, the insider owned 8,617 shares in the company, valued at $105,127.40. The trade was a 15.95% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Scott Bizily also recently made the following trade(s):

  • On Thursday, August 13th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.00, for a total value of $19,620.00.
  • On Tuesday, June 23rd, Scott Bizily sold 9,810 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.00, for a total value of $117,720.00.

4D Molecular Therapeutics Stock Up 13.9%

FDMT stock opened at $16.76 on Thursday. The stock’s fifty day simple moving average is $11.33 and its two-hundred day simple moving average is $10.03. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.05. 4D Molecular Therapeutics, Inc. has a 1-year low of $5.97 and a 1-year high of $16.93. The stock has a market cap of $925.82 million, a P/E ratio of -6.37 and a beta of 2.73.

4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). The business had revenue of $3.78 million for the quarter, compared to analysts’ expectations of $3.62 million. 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. Analysts expect that 4D Molecular Therapeutics, Inc. will post -4.09 EPS for the current year.

Wall Street Analyst Weigh In

FDMT has been the subject of a number of research analyst reports. The Goldman Sachs Group restated a “buy” rating and set a $32.00 price objective on shares of 4D Molecular Therapeutics in a report on Thursday, August 13th. HC Wainwright restated a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Monday, July 20th. Chardan Capital upgraded 4D Molecular Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. Wall Street Zen lowered 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $29.62.

Read Our Latest Research Report on FDMT

Institutional Trading of 4D Molecular Therapeutics

A number of institutional investors have recently modified their holdings of FDMT. Dynamic Technology Lab Private Ltd purchased a new position in 4D Molecular Therapeutics in the 1st quarter valued at approximately $39,000. Wexford Capital LP purchased a new position in shares of 4D Molecular Therapeutics in the third quarter valued at $41,000. AQR Capital Management LLC bought a new stake in shares of 4D Molecular Therapeutics during the 1st quarter valued at $46,000. Daiwa Securities Group Inc. lifted its holdings in 4D Molecular Therapeutics by 3,362.0% during the 4th quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock worth $48,000 after purchasing an additional 6,186 shares in the last quarter. Finally, Rangeley Capital LLC bought a new position in 4D Molecular Therapeutics in the 2nd quarter worth about $48,000. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

About 4D Molecular Therapeutics

(Get Free Report)

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.

Featured Articles